Ocular use of these agents has been associated with small increase in risk of systemic thromboembolic events, which may be significant in a few cases.[ 24 ] Moreover, intraocular injections of biosimilars are capable of inciting immunologic reactions.
← all excerpts
Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence.
1
—
—